Literature DB >> 3591814

Influenza: quantifying morbidity and mortality.

A S Monto.   

Abstract

Because of their dramatic impact, morbidity and mortality associated with influenza have been recognized since at least the time of Elizabeth I of England. Excess mortality has been documented since 1889, and the infamous 1918 outbreak confirmed that influenza was truly one of the last major plagues. Despite the clear recognition of large clusters of influenza activity, it is still difficult to quantify precisely the total impact of influenza morbidity and mortality, since laboratory confirmation is required for exact diagnosis. Many methods have been developed to provide estimates of the mortality associated with influenza. These methods are usually predicated on establishing expected baseline rates of mortality. Deaths in excess of these rates are then calculated--and attributed to the circulating influenza virus. In this way, groups at high risk of mortality have been defined as the elderly and those with chronic conditions. Special-risk groups, such as those in institutions, have also been identified. The quantification of morbidity has required different approaches, and here community and family studies have made major contributions. In contrast to mortality, morbidity is most pronounced in children and young adults, and the diseases, although self-limited, are often quite severe. Although the size of the outbreaks varies, influenza infection can be documented annually. Thus, each year must be considered an influenza year.

Entities:  

Mesh:

Year:  1987        PMID: 3591814     DOI: 10.1016/0002-9343(87)90556-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  28 in total

Review 1.  Individual and community impact of influenza.

Authors:  A S Monto
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

2.  Influenza vaccine match with circulating strains and indicators of influenza strain impact - Canada 1980 to 1992.

Authors:  E Ellis; J M Weber; W Cuff; S G Mackenzie
Journal:  Can J Infect Dis       Date:  1998-05

3.  Weekly monitoring of influenza impact in Belgium (1993-1995).

Authors:  R Snacken
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

4.  Breaking the barriers to childhood influenza vaccination.

Authors:  M M Ipp
Journal:  Paediatr Child Health       Date:  1998-09       Impact factor: 2.253

5.  Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site.

Authors:  Ramona Mögling; Mathilde J Richard; Stefan van der Vliet; Ruud van Beek; Eefje J A Schrauwen; Monique I Spronken; Guus F Rimmelzwaan; Ron A M Fouchier
Journal:  J Gen Virol       Date:  2017-06-13       Impact factor: 3.891

6.  Influenza surveillance.

Authors:  Y Ghendon
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

7.  Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

Authors:  Renée A J van Boxtel; Pauline Verdijk; Otto J de Boer; Elly van Riet; Tjeert T Mensinga; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 8.  Immunogenetics of seasonal influenza vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

9.  Air pollution, lagged effects of temperature, and mortality: The Netherlands 1979-87.

Authors:  J P Mackenbach; C W Looman; A E Kunst
Journal:  J Epidemiol Community Health       Date:  1993-04       Impact factor: 3.710

10.  Influenza pandemics in Singapore, a tropical, globally connected city.

Authors:  Vernon J Lee; Mark I Chen; Slew Pang Chan; Chia Siong Wong; Jeffery Cutter; Kee Tai Goh; Paul Anath Tambyah
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.